Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report), ...